Oligo-fucoidan + fucoxanthin + L-carnitine
Oligo-fucoidan + fucoxanthin + L-carnitine has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 21, 2026: “Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial”.
1 paper studies it6 findingsUpdated
1 new paper in 30 daysSee all 1 papers on oligo-fucoidan + fucoxanthin + L-carnitine
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“FFL also significantly lowered baseline-adjusted LDL (GMR = 0.85; 95% CI: 0.76-0.95; p < 0.01)”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Taipei Municipal Wan Fang Hospital and 1 more
- Human trial1
Studies in people
1 study gave oligo-fucoidan + fucoxanthin + L-carnitine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases urine albumin-to-creatinine ratioAdjusted 39.40% greater UACR reduction versus control; GMR 0.60 (95% CI 0.40–0.90); ITT: 32.18% greater reduction, GMR 0.67 (95% CI 0.48–0.93) no change: Has no effect on estimated glomerular filtration ratePP adjusted GMR 1.01, p = 0.74; ITT adjusted GMR 1.01, p = 0.78 down: Decreases LDLGMR 0.85 (95% CI 0.76–0.95); maximum 24.28% reduction in patients with baseline dyslipidemia | Randomized trial12 weeks | 55 peopleDKD patients receiving SGLT2 inhibitors (100%) and ACEIs/ARBs (85.5%); per-protocol analysis | Phytomedicine : international journal of phytotherapy and phytopharmacology, Oct 21, 2026 |
What did studies of oligo-fucoidan + fucoxanthin + L-carnitine find?
6Studies of oligo-fucoidan + fucoxanthin + L-carnitine measured 6 outcomes, among them LDL, estimated glomerular filtration rate and urine albumin-to-creatinine ratio.
LDL
downin humans1
1 study
LDL
downin humans1
Oligo-fucoidan + fucoxanthin + L-carnitine decreases LDL in humans (DKD patients receiving adjunctive FFL) (GMR 0.85 (95% CI 0.76–0.95); maximum 24.28% reduction in patients with baseline dyslipidemia).
“FFL also significantly lowered baseline-adjusted LDL (GMR = 0.85; 95% CI: 0.76-0.95; p < 0.01)”
Human trialDKD patients receiving adjunctive FFLstandardized marine formula12 weeks
Phytomedicine : international journal of phytotherapy and phytopharmacology
Estimated glomerular filtration rate
no changein humans1
1 study
Estimated glomerular filtration rate
no changein humans1
Oligo-fucoidan + fucoxanthin + L-carnitine showed no clear effect on estimated glomerular filtration rate in humans (DKD patients receiving adjunctive FFL; per-protocol analysis) (PP adjusted GMR 1.01, p = 0.74; ITT adjusted GMR 1.01, p = 0.78).
“eGFR remained stable and preserved over 12 weeks (PP adjusted GMR = 1.01, p = 0.74; ITT adjusted GMR = 1.01, p = 0.78).”
Human trialDKD patients receiving adjunctive FFL; per-protocol analysisstandardized marine formula12 weeksn = 55
Phytomedicine : international journal of phytotherapy and phytopharmacology
Urine albumin-to-creatinine ratio
downin humans1
1 study
Urine albumin-to-creatinine ratio
downin humans1
Oligo-fucoidan + fucoxanthin + L-carnitine decreases urine albumin-to-creatinine ratio in humans (Adjusted 39.40% greater UACR reduction versus control; GMR 0.60 (95% CI 0.40–0.90); ITT: 32.18% greater reduction, GMR 0.67 (95% CI 0.48–0.93)).
“adjunctive FFL achieved a highly significant, adjusted 39.40% greater reduction in UACR compared to control”
Human trialDKD patients receiving SGLT2 inhibitors (100%) and ACEIs/ARBs (85.5%); per-protocol analysisstandardized marine formula12 weeksn = 55
Phytomedicine : international journal of phytotherapy and phytopharmacology
Inflammation
downin mice1
1 study
Inflammation
downin mice1
Oligo-fucoidan + fucoxanthin + L-carnitine decreases inflammation in mice (diabetic CKD).
“Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”
Animalsdiabetic CKDstandardized marine formulakidney8 weeks
Phytomedicine : international journal of phytotherapy and phytopharmacology
Tubulointerstitial fibrosis
downin mice1
1 study
Tubulointerstitial fibrosis
downin mice1
Oligo-fucoidan + fucoxanthin + L-carnitine decreases tubulointerstitial fibrosis in mice (diabetic CKD).
“Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”
Animalsdiabetic CKDstandardized marine formulakidney8 weeks
Phytomedicine : international journal of phytotherapy and phytopharmacology
Renal dysfunction
downin mice1
1 study
Renal dysfunction
downin mice1
Oligo-fucoidan + fucoxanthin + L-carnitine decreases renal dysfunction in mice (diabetic CKD).
“Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”
Animalsdiabetic CKDstandardized marine formulakidney8 weeks
Phytomedicine : international journal of phytotherapy and phytopharmacology